What Is 2-hydroxyglutarate synthase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2-hydroxyglutarate synthase is an enzyme that catalyzes the conversion of 2-oxoglutarate to 2-hydroxyglutarate, a metabolite linked to cellular redox balance and epigenetic regulation. It is not a standard enzyme in primary metabolism but may arise under pathological conditions or in engineered pathways, with implications in cancer and mitochondrial disorders.

Key Facts

2-hydroxyglutarate synthase is not a canonical enzyme but may refer to promiscuous activity of other enzymes
The oncometabolite D-2-hydroxyglutarate accumulates in IDH1/2-mutant cancers
Mutations in IDH1/2 genes are found in ~80% of grade II–III gliomas
2-hydroxyglutarate levels can exceed 5 mmol/kg in tumor tissues with IDH mutations
Elevated 2-HG disrupts α-ketoglutarate-dependent dioxygenases, altering DNA methylation

Overview

2-hydroxyglutarate synthase is not a standard enzyme encoded directly in the human genome but refers to enzymatic activities that produce 2-hydroxyglutarate (2-HG), particularly D-2-hydroxyglutarate. This metabolite is primarily generated through abnormal function of isocitrate dehydrogenase (IDH) enzymes, especially when mutated in cancers.

Unlike typical metabolic enzymes, 2-hydroxyglutarate production arises from neomorphic activity—where a mutated enzyme gains a new function. This process is central to understanding tumorigenesis in gliomas and acute myeloid leukemia (AML), where D-2-HG acts as an oncometabolite.

Enzyme promiscuity: Mutant IDH1 and IDH2 exhibit altered substrate specificity, reducing 2-oxoglutarate to D-2-hydroxyglutarate instead of catalyzing normal TCA cycle reactions.
Oncometabolite accumulation: D-2-hydroxyglutarate can reach concentrations exceeding 5 mmol/kg tissue in IDH-mutant gliomas, disrupting normal cellular differentiation.
Genetic basis: Over 70% of secondary glioblastomas harbor IDH1 R132H mutations, making this one of the most common mutations in diffuse gliomas.
Stereochemistry matters: The D-enantiomer of 2-HG is oncogenic, while L-2-HG may accumulate under hypoxia but has different regulatory roles.
Diagnostic utility: Detection of elevated D-2-HG via MRS (magnetic resonance spectroscopy) is used non-invasively to monitor tumor progression and treatment response.

How It Works

The production of 2-hydroxyglutarate occurs through altered catalytic activity in specific metabolic enzymes, primarily isocitrate dehydrogenases, under pathological conditions such as cancer.

Neomorphic enzyme activity: Mutant IDH1/2 gains a new function—converting 2-oxoglutarate to D-2-HG using NADPH, a reaction not seen in the wild-type enzyme.
Redox imbalance: The reaction consumes NADPH, potentially compromising cellular antioxidant defenses and increasing oxidative stress in tumor cells.
Competitive inhibition: D-2-HG structurally resembles 2-oxoglutarate and inhibits α-ketoglutarate-dependent dioxygenases, including TET and JmjC-domain histone demethylases.
Epigenetic dysregulation: Inhibition of these enzymes leads to global hypermethylation of DNA and histones, blocking cellular differentiation and promoting a stem-like state.
Metabolic feedback: High levels of D-2-HG suppress prolyl hydroxylases, stabilizing HIF-1α and promoting angiogenesis even under normoxic conditions.
Enzyme kinetics: The Km of mutant IDH2 for 2-oxoglutarate is approximately 10-fold higher than wild-type, favoring 2-HG production under high substrate conditions.

Comparison at a Glance

Below is a comparison of wild-type IDH enzymes versus mutant forms that produce 2-hydroxyglutarate:

Property	Wild-Type IDH1/2	Mutant IDH1/2 (e.g., R132H)
Primary Reaction	Oxidative decarboxylation of isocitrate to 2-oxoglutarate	Reduction of 2-oxoglutarate to D-2-hydroxyglutarate
Normal Function	Part of TCA cycle, produces NADPH	Loss of normal function, gains neomorphic activity
2-HG Production	Negligible	Up to 35-fold increase in tumors
Cancer Association	None	Present in ~80% of low-grade gliomas
Therapeutic Target	No	Yes—ivosidenib inhibits mutant IDH1

This shift in enzyme function has major implications for cancer diagnostics and therapy. The mutant enzymes not only disrupt normal metabolism but also alter the epigenetic landscape, making them actionable targets. Detection of 2-HG in serum or tumor tissue is now a biomarker for IDH-mutant cancers, guiding treatment decisions.

Why It Matters

Understanding 2-hydroxyglutarate production is critical for oncology, metabolic disease research, and drug development. Its role as an oncometabolite has reshaped how scientists view cancer metabolism.

Targeted therapies:Ivosidenib, approved by the FDA in 2018, inhibits mutant IDH1 and reduces D-2-HG levels by over 90% in AML patients.
Diagnostic imaging: D-2-HG can be detected in vivo using 1H-MRS at 3T and 7T MRI, enabling non-invasive tumor monitoring.
Prognostic marker: IDH-mutant gliomas have a median survival of 3–5 years longer than IDH-wild-type counterparts.
Therapeutic resistance: Persistent 2-HG production may contribute to epigenetic plasticity, allowing tumor cells to adapt under therapy.
Autoimmune implications: Elevated D-2-HG has been linked to T-cell dysfunction in tumor microenvironments, suppressing immune response.
Metabolic disorders: Germline mutations in D2HGDH cause D-2-hydroxyglutaric aciduria, a rare neurometabolic disease with developmental delays.

As research advances, targeting 2-hydroxyglutarate pathways offers promising strategies for cancer treatment and early diagnosis. The enzyme’s indirect role underscores the complexity of metabolic reprogramming in disease.